Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
Completed · Phase 3
Conditions studied: Asthma
In brief
This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.
Key facts
- Study ID
- NCT05274815
- Run by
- AstraZeneca
- People needed
- 305
- Starts
- 2022-05-17
- Expected to finish
- 2024-09-09
- Last updated by the study team
- 2025-12-11
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Newark, Delaware, United States
- Research Site — Loxahatchee Groves, Florida, United States
- Research Site — Ann Arbor, Michigan, United States
- Research Site — Toms River, New Jersey, United States
- Research Site — The Bronx, New York, United States
- Research Site — DuBois, Pennsylvania, United States
- Research Site — Buenos Aires, Argentina
- Research Site — CABA, Argentina
- Research Site — CABA, Argentina
- Research Site — Mendoza, Argentina
- Research Site — Monte Grande, Argentina
- Research Site — Pilar, Argentina
- Research Site — Quilmes, Argentina
- Research Site — Ranelagh, Argentina
- Research Site — Rosario, Argentina
- Research Site — San Fernando, Argentina
- Research Site — San Juan Bautista, Argentina
- Research Site — San Miguel de Tucumán, Argentina
- Research Site — Brussels (Woluwé-St-Lambert), Belgium
- Research Site — Erpent, Belgium
- Research Site — Ghent, Belgium
- Research Site — Liège, Belgium
- Research Site — Haskovo, Bulgaria
- Research Site — Razgrad, Bulgaria
- Research Site — Newport Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.